OYST Stock Performance, Insider Transaction and News

OYST - Oyster Point Pharma, Inc.

Market Cap	299.85M	P/E	-	EPS this Y	-63.00%	Ern Qtrly Grth	-
Income	-176.64M	Forward P/E	-3.50	EPS next Y	49.40%	50D Avg Chg	1.00%
Sales	19.58M	PEG	-	EPS past 5Y	-	200D Avg Chg	53.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-17.00%
Recommedations	2.50	Quick Ratio	2.81	Shares Outstanding	26.84M	52W Low Chg	223.00%
Insider Own	1.49%	ROA	-65.11%	Shares Float	8.83M	Beta	1.32
Inst Own	87.16%	ROE	-306.38%	Shares Shorted/Prior	288.83K/434.36K	Price	11.17
Gross Margin	76.93%	Profit Margin	-	Avg. Volume	417,562	Target Price	27.50
Oper. Margin	-809.09%	Earnings Date	Feb 22	Volume	2,088,283	Change	0.00%

Healthcare | Biotechnology | United States

About Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

OYST Chatroom

TrendyChart Posted - 10/30/23

Upcoming Earnings Report: $OYST Oyster Point Pharma will be reporting on 11/10/2023 at 4:00PM | Do you have a rosy or gloomy earnings perspective for this stock?

TrendyChart Posted - 10/30/23

Upcoming Earnings Report: $OYST Oyster Point Pharma will be reporting on 11/10/2023 at 4:00PM | Are you anticipating good or poor earnings numbers for this stock?

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $OYST Oyster Point Pharma will be reporting on 10/13/2023 at 4:00PM | What's your take on the earnings potential of this stock?

nmjc Posted - 07/30/23

@Biotechace exactly, this will be a LONG hold now. I bought the approval dip bc that was crazy and sold Friday. Look at what has happened to $KALA and $OYST we wait now thill $TARS sells out and we get a shot squeeze but the medium term too is in. See ya in 6 months

barry13 Posted - 1 year ago

@Kingjake26 @BB94 @QuMan There a heck a lot of competition for DED now and its not clear if Rexpro is going to make a huge dent. $VTRS recently acquired $OYST to secure Tyrvara which looks like will become the leader in the space. When you look head-to-head, in the Schrimer test which is the standard for DED, Rexpro causes about a 4 mm change in the Schrimer test by the end of Day 1 after 4 doses, but Tyrvara causes a 16-17 mm change in the test within 5 minutes of the first dose, so it generates more tears with a much faster onset of action. Tyrvara also has the advantage of being a nasal spray which has the benefit of sparing the eye from additional chemicals and many might prefer a nasal spray over eye drops.

risenhoover Posted - 03/26/23

$OYST OYST / Oyster Point Pharma Inc Price Target Updated https://fintel.io/sfo/us/oyst?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$OYST OYST / Oyster Point Pharma Inc Price Target Updated https://fintel.io/sfo/us/oyst?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/24/23

$OYST OYST / Oyster Point Pharma Inc Price Target Updated https://fintel.io/sfo/us/oyst?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/23/23

$OYST OYST / Oyster Point Pharma Inc Price Target Updated https://fintel.io/sfo/us/oyst?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/22/23

$OYST OYST / Oyster Point Pharma Inc Price Target Updated https://fintel.io/sfo/us/oyst?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget